Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

"We have data from various studies—in particular the [phase 3] postMONARCH study [NCT05169567]—that helped establish that there could potentially be a role for switching endocrine therapy and, for the most part, switching a CDK4/6 inhibitor."

Kevin Kalinsky, MD, MS, a professor and director of the Division of Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and the Louisa and Rand Glenn Family Chair in Breast Cancer Research and director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, discusses the potential for switching CDK4/6 inhibitors in patients with metastatic hormone receptor–positive metastatic breast cancer and the factors that could inform this approach.